Loading...
XKRX
214450
Market cap4.06bUSD
Jul 25, Last price  
558,000.00KRW
1D
-3.63%
1Q
48.60%
Jan 2017
1,281.19%
IPO
391.20%
Name

PharmaResearch Co Ltd

Chart & Performance

D1W1MN
No data to show
P/E
60.99
P/S
16.04
EPS
9,148.41
Div Yield, %
Shrs. gr., 5y
7.09%
Rev. gr., 5y
33.08%
Revenues
350.12b
+34.14%
37,454,866,93345,953,114,75754,469,757,89164,280,682,05683,871,642,044108,745,921,878154,082,897,894194,758,643,934261,010,910,560350,115,068,640
Net income
92.04b
+20.24%
12,877,827,17213,909,058,67712,955,558,10714,408,301,97416,667,485,00432,774,330,37046,688,655,71040,576,699,24076,551,213,75092,043,313,160
CFO
138.12b
+112.67%
16,022,957,5838,161,008,6038,643,379,0465,203,397,41819,273,230,95132,391,668,89065,297,140,55459,403,807,96664,945,249,410138,121,879,150
Dividend
Dec 27, 2023660 KRW/sh
Earnings
Aug 05, 2025

Profile

PharmaResearch Co., Ltd. operates as a biopharmaceutical company in South Korea. The company offers Re-An eye drops for protecting eyes from corneal damages with various causes; Rejuvenex injection, a tissue regeneration activator that regenerates connective tissues, including ligament, tendon, skin, etc.; Rejuvenex cream, which treats the wound through rapid tissue regeneration; REJURAN HEALER, an intra dermal injection to enhance elasticity, turgidity, and tonicity of skin; Rejuran i and Rejuran s intra dermal or cannula injections; REJURAN moisturizer for daily skin protection; REJURAN concentrate for sensitive and aged skin; REJURAN healing eye gel; REJURAN healing cream and mask; REJURAN sunscreen that protects skin from UV rays; and REJURAN recover soothing mask. It also provides D+CELL 350 TRA concentrated rejuvenation cream, intensive repair serum, activating facial toner, high potency eye lift, moisture balancer, mask, hair, cream, and hydro products; REJURAN tone-up booster; and CLEVIEL prime plus and contour plus with lidocaine medical devices, as well as CONJURAN medical devices. In addition, the company offers functional foods under the REJULINE, REJUSHINE, and REJULIGHT brands. The company was formerly known as Pharma Research Products Co., Ltd. and changed its name to PharmaResearch Co., Ltd. in April 2021. PharmaResearch Co., Ltd. was founded in 1993 and is headquartered in Seongnam, South Korea.
IPO date
Jul 24, 2015
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
350,115,069
34.14%
261,010,911
34.02%
194,758,644
26.40%
Cost of revenue
180,010,321
132,109,057
105,522,831
Unusual Expense (Income)
NOPBT
170,104,748
128,901,854
89,235,813
NOPBT Margin
48.59%
49.39%
45.82%
Operating Taxes
26,869,723
23,439,915
10,613,904
Tax Rate
15.80%
18.18%
11.89%
NOPAT
143,235,025
105,461,939
78,621,909
Net income
92,043,313
20.24%
76,551,214
88.66%
40,576,699
-13.09%
Dividends
(10,090,447)
(7,529,103)
(6,315,548)
Dividend yield
0.29%
0.65%
0.91%
Proceeds from repurchase of equity
359,235
BB yield
-0.03%
Debt
Debt current
11,800,370
33,006,061
20,574,144
Long-term debt
5,879,485
1,481,343
46,194,233
Deferred revenue
835,476
Other long-term liabilities
198,948,466
6,663,909
2,210,924
Net debt
(233,478,968)
(244,234,943)
(183,035,266)
Cash flow
Cash from operating activities
138,121,879
64,945,249
59,403,808
CAPEX
(36,414,698)
(12,062,682)
(17,757,766)
Cash from investing activities
(225,538,403)
(44,667,653)
(11,907,643)
Cash from financing activities
182,643,386
(25,968,629)
(9,301,361)
FCF
124,085,049
55,053,360
63,570,103
Balance
Cash
437,351,073
160,298,060
184,343,338
Long term investments
(186,192,250)
118,424,288
65,460,304
Excess cash
233,653,070
265,671,802
240,065,710
Stockholders' equity
378,354,751
304,560,417
234,324,630
Invested Capital
518,835,715
236,715,954
196,174,409
ROIC
37.92%
48.72%
39.85%
ROCE
21.68%
25.66%
20.55%
EV
Common stock shares outstanding
13,292
10,559
9,976
Price
262,500.00
139.73%
109,500.00
56.65%
69,900.00
-14.76%
Market cap
3,489,081,488
201.76%
1,156,238,094
65.81%
697,316,319
-15.41%
EV
3,285,641,007
957,343,523
542,434,045
EBITDA
183,749,981
140,897,450
99,982,856
EV/EBITDA
17.88
6.79
5.43
Interest
4,634,271
2,987,196
3,830,064
Interest/NOPBT
2.72%
2.32%
4.29%